Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.58
$1.42
$0.97
$2.73
$490.75M2.356.24 million shs7.94 million shs
Revvity Inc. stock logo
RVTY
Revvity
$100.28
-0.2%
$92.32
$81.22
$118.30
$11.21B1.111.67 million shs1.42 million shs
10x Genomics stock logo
TXG
10x Genomics
$30.71
+3.8%
$22.67
$8.94
$31.15
$3.76B2.122.85 million shs3.09 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
0.00%+25.40%-1.25%+1.28%+59.98%
Revvity Inc. stock logo
RVTY
Revvity
-0.16%+3.71%+15.59%+1.82%+12.35%
10x Genomics stock logo
TXG
10x Genomics
+3.79%+24.74%+36.91%+37.28%+224.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.58
$1.42
$0.97
$2.73
$490.75M2.356.24 million shs7.94 million shs
Revvity Inc. stock logo
RVTY
Revvity
$100.28
-0.2%
$92.32
$81.22
$118.30
$11.21B1.111.67 million shs1.42 million shs
10x Genomics stock logo
TXG
10x Genomics
$30.71
+3.8%
$22.67
$8.94
$31.15
$3.76B2.122.85 million shs3.09 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
0.00%+25.40%-1.25%+1.28%+59.98%
Revvity Inc. stock logo
RVTY
Revvity
-0.16%+3.71%+15.59%+1.82%+12.35%
10x Genomics stock logo
TXG
10x Genomics
+3.79%+24.74%+36.91%+37.28%+224.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.80
Reduce$1.8316.03% Upside
Revvity Inc. stock logo
RVTY
Revvity
2.21
Hold$107.737.43% Upside
10x Genomics stock logo
TXG
10x Genomics
2.20
Hold$23.17-24.56% Downside

Current Analyst Ratings Breakdown

Latest TXG, PACB, and RVTY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2026
Revvity Inc. stock logo
RVTY
Revvity
Initiated CoveragePeer Perform
5/18/2026
10x Genomics stock logo
TXG
10x Genomics
DowngradeStrong-BuyHold
5/13/2026
Revvity Inc. stock logo
RVTY
Revvity
DowngradeSell (D+)Sell (D)
5/12/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetEqual Weight$20.00 ➝ $22.00
5/12/2026
10x Genomics stock logo
TXG
10x Genomics
Boost Price TargetNeutral$17.00 ➝ $20.00
5/11/2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Boost Price TargetUnderweight$1.00 ➝ $1.50
5/7/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetEqual Weight$95.00 ➝ $105.00
5/6/2026
Revvity Inc. stock logo
RVTY
Revvity
Lower Price TargetHold$110.00 ➝ $100.00
5/6/2026
Revvity Inc. stock logo
RVTY
Revvity
Set Price Target$117.00
5/6/2026
Revvity Inc. stock logo
RVTY
Revvity
Lower Price TargetNeutral$96.00 ➝ $90.00
5/6/2026
Revvity Inc. stock logo
RVTY
Revvity
Boost Price TargetBuy$115.00 ➝ $120.00
(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$160.01M3.07$0.79 per share2.00$0.02 per share79.00
Revvity Inc. stock logo
RVTY
Revvity
$2.90B3.85$8.80 per share11.40$63.95 per share1.57
10x Genomics stock logo
TXG
10x Genomics
$642.82M6.07N/AN/A$6.24 per share4.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$546.38M-$0.43N/AN/AN/A-80.35%-571.06%-18.82%8/3/2026 (Estimated)
Revvity Inc. stock logo
RVTY
Revvity
$241.20M$2.0947.9817.352.208.26%8.00%4.83%7/27/2026 (Estimated)
10x Genomics stock logo
TXG
10x Genomics
-$43.54M-$0.17N/AN/AN/A-3.55%-2.86%-2.23%8/6/2026 (Estimated)

Latest TXG, PACB, and RVTY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.17-$0.12+$0.05-$0.03$39.94 million$37.18 million
5/7/2026Q1 2026
10x Genomics stock logo
TXG
10x Genomics
-$0.29-$0.10+$0.19-$0.10$146.41 million$150.84 million
5/5/2026Q1 2026
Revvity Inc. stock logo
RVTY
Revvity
$1.02$1.06+$0.04$0.36$704.07 million$711.12 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Revvity Inc. stock logo
RVTY
Revvity
$0.280.28%N/A13.40%N/A
10x Genomics stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Latest TXG, PACB, and RVTY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2026
Revvity Inc. stock logo
RVTY
Revvity
quarterly$0.070.32%7/17/20267/17/20268/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
5.65
4.87
Revvity Inc. stock logo
RVTY
Revvity
0.37
1.72
1.41
10x Genomics stock logo
TXG
10x Genomics
N/A
5.90
5.42

Institutional Ownership

CompanyInstitutional Ownership
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A
Revvity Inc. stock logo
RVTY
Revvity
86.65%
10x Genomics stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
3.70%
Revvity Inc. stock logo
RVTY
Revvity
0.85%
10x Genomics stock logo
TXG
10x Genomics
8.84%
CompanyEmployeesShares OutstandingFree FloatOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730310.60 million299.11 millionOptionable
Revvity Inc. stock logo
RVTY
Revvity
11,000111.56 million110.61 millionOptionable
10x Genomics stock logo
TXG
10x Genomics
1,240126.96 million115.73 millionOptionable

Recent News About These Companies

10x Genomics (TXG) Q1 2026 Earnings Transcript
10x Genomics Q1 Earnings Call Highlights
10x Genomics: Q1 Earnings Snapshot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.58 0.00 (0.00%)
Closing price 06/2/2026 04:00 PM Eastern
Extended Trading
$1.57 -0.01 (-0.63%)
As of 08:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Revvity stock logo

Revvity NYSE:RVTY

$100.28 -0.24 (-0.24%)
Closing price 06/2/2026 03:59 PM Eastern
Extended Trading
$100.11 -0.17 (-0.17%)
As of 08:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

10x Genomics stock logo

10x Genomics NASDAQ:TXG

$30.71 +1.12 (+3.79%)
Closing price 06/2/2026 04:00 PM Eastern
Extended Trading
$31.14 +0.43 (+1.38%)
As of 08:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.